Mechanistic Insights from REDUCE-IT STRENGTHen the Case Against Triglyceride Lowering as a Strategy for Cardiovascular Disease Risk Reduction

Elevated triglyceride (TG) levels have been linked to residual atherosclerotic cardiovascular risk in patients with controlled low-density lipoprotein cholesterol (LDL-C). However, outcome trials testing TG-lowering agents have failed to demonstrate cardiovascular risk reduction in statin-treated subjects. One such example is the recent STRENGTH trial, which tested mixed omega fatty acids (n3-FAs, 4g/d) in high-risk patients with elevated TGs. Similar to trials using fibrates and niacin, STRENGTH failed despite effective TG-lowering.
Source: The American Journal of Medicine - Category: General Medicine Authors: Tags: Commentary Source Type: research